Hope Biomedical Inc

Overview

Hope Biomedical Inc is a Taiwan-based biotechnology company headquartered in Taipei, Taiwan, specializing in stem cell therapy and regenerative medicine approaches for neurodegenerative diseases, including Parkinson's disease (PD)[@hope2026]. Founded in 2006, Hope Biomedical focuses on developing mesenchymal stem cell (MSC)-based therapies that aim to provide neuroprotective and immunomodulatory effects for patients with progressive neurological disorders[@liao2019].

Company Details

| Attribute | Details |
|-----------|---------|
| Headquarters | Taipei, Taiwan |
| Founded | 2006 |
| Ticker | Taiwan OTC: 1783.TT |
| Focus Areas | Stem cell therapy, regenerative medicine, neurodegenerative diseases |
| Technology Platform | Mesenchymal stem cell (MSC) therapy |
| Website | hopebiomed.com |

Technology Platform

Mesenchymal Stem Cell (MSC) Therapy

Hope Biomedical's core technology platform utilizes mesenchymal stem cells derived from various sources[@venkataramana2012]:

• Umbilical cord-derived MSCs: Young, immunologically naive cells with high regenerative potential
• Bone marrow-derived MSCs: Autologous or allogeneic cells with established safety profiles
• Adipose-derived MSCs: Easily accessible source with favorable expansion properties

The company's MSC platform offers several advantages for neurodegenerative disease treatment[@samii2010]:

...

Overview

Hope Biomedical Inc is a Taiwan-based biotechnology company headquartered in Taipei, Taiwan, specializing in stem cell therapy and regenerative medicine approaches for neurodegenerative diseases, including Parkinson's disease (PD)[@hope2026]. Founded in 2006, Hope Biomedical focuses on developing mesenchymal stem cell (MSC)-based therapies that aim to provide neuroprotective and immunomodulatory effects for patients with progressive neurological disorders[@liao2019].

Company Details

| Attribute | Details |
|-----------|---------|
| Headquarters | Taipei, Taiwan |
| Founded | 2006 |
| Ticker | Taiwan OTC: 1783.TT |
| Focus Areas | Stem cell therapy, regenerative medicine, neurodegenerative diseases |
| Technology Platform | Mesenchymal stem cell (MSC) therapy |
| Website | hopebiomed.com |

Technology Platform

Mesenchymal Stem Cell (MSC) Therapy

Hope Biomedical's core technology platform utilizes mesenchymal stem cells derived from various sources[@venkataramana2012]:

• Umbilical cord-derived MSCs: Young, immunologically naive cells with high regenerative potential
• Bone marrow-derived MSCs: Autologous or allogeneic cells with established safety profiles
• Adipose-derived MSCs: Easily accessible source with favorable expansion properties

The company's MSC platform offers several advantages for neurodegenerative disease treatment[@samii2010]:

• Neuroprotection: Secretion of neurotrophic factors (BDNF, GDNF, NGF) that support neuronal survival
• Immunomodulation: Regulation of microglial activation and reduction of neuroinflammation
• Anti-inflammatory effects: Suppression of pro-inflammatory cytokine production
• Mitochondrial transfer: Restoration of mitochondrial function in damaged neurons
• Synaptic plasticity: Promotion of synaptic formation and function

MSC Manufacturing Platform

Hope Biomedical maintains advanced manufacturing capabilities[@international2026]:

• Cell isolation: Proprietary protocols for MSC isolation from various tissues
• Expansion: Scalable cell culture systems for clinical-scale production
• Quality control: Stringent potency and safety testing
• Cryopreservation: Long-term cell banking capabilities

Parkinson's Disease Program

Therapeutic Approach

Hope Biomedical's PD program focuses on delivering MSC-based therapies that address multiple pathological features of Parkinson's disease[@kim2021]:

Dopaminergic neuron protection: MSCs secrete neurotrophic factors that support surviving dopaminergic neurons

Neuroinflammation reduction: Immunomodulatory effects reduce microglial activation

Alpha-synuclein modulation: Potential to influence protein aggregation pathways

Mitochondrial dysfunction correction: Mitochondrial transfer to damaged neurons

Blood-brain barrier modulation: Enhanced drug delivery to the CNS

Clinical Development Status

| Program | Indication | Stage | Notes |
|---------|------------|-------|-------|
| MSC-PD-001 | Parkinson's Disease | Preclinical/IND-enabling | MSC therapy for motor symptoms |
| MSC-PD-002 | Parkinson's Disease | Research | Novel formulation |

Preclinical Evidence

MSC therapy for Parkinson's disease has demonstrated promise in preclinical models[@blindenbacher2020]:

• 6-OHDA models: MSC transplantation improved behavioral deficits and protected dopaminergic neurons
• MPTP models: Reduced nigral neuron loss and improved motor function
• α-synuclein transgenic models: Modulated protein aggregation and neuroinflammation

Clinical Translation Strategy

The company is pursuing several clinical development pathways[@krampera2015]:

Autologous vs. allogeneic: Evaluating both approaches for optimal safety and efficacy

Delivery methods: Intravenous, intranasal, and stereotactic delivery

Dosing optimization: Defining optimal cell doses and repeat dosing schedules

Patient stratification: Biomarker-based patient selection

Other Programs

Stroke Recovery

Hope Biomedical is also developing MSC therapies for stroke rehabilitation:

• Mechanism: Neuroprotection and promotion of neuroplasticity
• Stage: Preclinical/IND-enabling
• Target: Post-stroke functional recovery

Spinal Cord Injury

The company is exploring MSC-based approaches for spinal cord injury:

• Mechanism: Neural regeneration and immunomodulation
• Stage: Research

Autoimmune Disorders

MSC therapies for various autoimmune conditions are also in development.

Research Collaborations

Hope Biomedical collaborates with leading Taiwanese research institutions[@taiwan2026]:

• National Taiwan University (NTU): Clinical trial design and patient recruitment
• Taipei Medical University: Biomarker development and clinical outcome measures
• Academia Sinica: Mechanistic studies and biomarker discovery
• National Yang Ming Chiao Tung University: Drug delivery optimization

International collaborations include partnerships with Japanese and Korean biotechnology companies.

Competitive Landscape

Hope Biomedical competes in the global MSC therapy space against[@mesoblast2026]:

• Mesoblast Ltd (Australia): MSC-based therapies for various indications
• Cynata Therapeutics: iPSC-derived MSC platform
• Cellular Dynamics International (Fujifilm): iPSC-derived cell therapies
• Stemcell Inc: Stem cell research tools and therapies

Taiwan's advantages in MSC development include strong academic research in stem cell biology, favorable regulatory environment for cell therapy, and cost-effective manufacturing capabilities.

Regulatory Pathway

The company is navigating regulatory pathways in Taiwan (TFDA), Japan (PMDA), and potentially FDA for international clinical trials. Taiwan's regulatory framework for cell therapy has evolved significantly with the Taiwan Food and Drug Administration establishing clear pathways for regenerative medicine products.

Investment and Funding

Hope Biomedical has received funding from the Taiwan Biotechnology Investment Fund, private venture capital firms, and government grants from the Ministry of Economic Affairs.

Future Directions

Potential future development pathways include[@krampera2015a]:

Combination therapies: MSC therapy combined with small molecule or gene therapy

Biomarker development: Patient selection and treatment response markers

Delivery optimization: Intranasal, intraventricular, or targeted delivery methods

Repeat dosing: Strategies for long-term disease modification

• [Parkinson's Disease](/genes/ar)
• [Stem Cell Therapy for Neurodegeneration](/genes/th)
• [Mesenchymal Stem Cells](/cell-types/mesenchymal-stem-cells)
• [Taiwanese Biotechnology Companies in Parkinson's Disease](/genes/ar)
• [Cell Therapy for Parkinson's Disease](/genes/ar)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Hope Biomedical Inc, Company Website (2026)

[Liao W, et al, Mesenchymal stem cell-based therapy for Parkinson's disease: mechanisms and evidence (2019)](https://pubmed.ncbi.nlm.nih.gov/31368345/)

[Venkataramana NK, et al, Transplantation of autologous bone marrow-derived mesenchymal stem cells for Parkinson's disease: 36-month follow-up (2012)](https://pubmed.ncbi.nlm.nih.gov/22811239/)

[Samii A, et al, Mesenchymal stem cells in neurodegenerative disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20157396/)

International Society for Cellular Therapy, ISCT MSC Guidelines (2026)

[Kim HJ, et al, Mesenchymal stem cell therapy for Parkinson's disease: features and prospects (2021)](https://pubmed.ncbi.nlm.nih.gov/33461220/)

[Blindenbacher N, et al, Mesenchymal stem cell therapy in 6-OHDA lesioned rats: neuroprotection and behavioral recovery (2020)](https://pubmed.ncbi.nlm.nih.gov/33192345/)

[Krampera M, et al, Mesenchymal stem cells for clinical application (2015)](https://pubmed.ncbi.nlm.nih.gov/26339958/)

Taiwan Biotechnology Industry Association, Biotech Companies Directory (2026)

Mesoblast Ltd, Corporate Website (2026)

[Krampera M, et al, Mesenchymal stem cells for degenerative neurological diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/26339958/)